Research on MORE and Mindfulness Covered in the News

Results from a new Stage 2 randomized controlled trial of Mindfulness-Oriented Recovery Enhancement (MORE), to be published later this summer in the Journal of Consulting and Clinical Psychology, have been covered in a news story that also details findings from a recently published study of the effects of mindfulness on deautomatization of habit behaviors. A second news story also did a really nice job describing results from this study.

Results from this study, conducted in 95 people with chronic pain who had been prescribed long-term opioid therapy, demonstrate that MORE significantly decreased chronic pain intensity and significantly decreased the risk of future opioid misuse. Further, MORE boosted a range of positive psychological functions, including positive emotions, savoring, meaning in life, and the sense of self-transcendence. Importantly, the MORE’s effects on reducing pain and opioid misuse were linked with these increases in positive psychological functioning, suggesting that teaching people to “savor the good” and increase the sense of joy, meaningfulness, and natural healthy pleasure in life may be an antidote to the current pain and opioid crises in America – modern epidemics that have been termed “diseases of despair.”

This is the second randomized controlled trial to demonstrate therapeutic effects of MORE on chronic pain symptoms and opioid misuse, providing compelling evidence of MORE’s efficacy as a means of alleviating the suffering caused by the opioid crisis.

Dr. Garland Appointed to NIH HEAL Multi-disciplinary Workgroup

Eric Garland, PhD has been appointed by Francis Collins, MD, PhD, Director of the National Institutes of Health, to the NIH HEAL Multidisciplinary Working Group focused on a $1.1 billion federal effort to speed scientific solutions to stem the opioid crisis.

The Helping to End Addiction Long-term (HEAL) Initiative’s working group—comprised of 16 national experts on issues of pain and addiction research—is part of NIH’s efforts to “bring the very best science to the task of addressing our national crisis of opioid addiction and chronic pain,” explained Collins.

The working group is charged with providing input on HEAL research, drafting recommendations for various NIH institute and federal advisory committees, prioritizing future research areas, increasing harmonization across HEAL research projects, offering input on proposed funding plans and providing a public venue for discussion of HEAL research by stakeholders, among other tasks.

Garland is director of the Center on Mindfulness and Integrative Health Intervention Development (C-MIIND) and the developer of Mindfulness-Oriented Recovery Enhancement (MORE), an innovative mind-body therapy designed to address addiction, pain and stress.

His current research program, supported by nearly $50 million in grant funding, focuses on testing MORE and other behavioral therapies for chronic pain and opioid misuse. In addition to providing care to hundreds of study participants, his work is also contributing to a deeper understanding of the neuroscience behind pain, addictive behaviors and their effects on reward processing in the brain.

“I am deeply humbled by the opportunity to serve on this national working group,” said Garland. “The current opioid crisis is one of the greatest and most urgent public health issues confronting society today. I’m tremendously honored to work closely with NIH and contribute what I’ve learned to advance scientific solutions to this grand challenge.”

Research on MORE Covered by NIDA: Prescription Opioid Misuse Treatment Leverages Mindfulness To Amplify Natural Rewards

nidaThe National Institute on Drug Abuse (NIDA) covered a recently published study of Mindfulness-Oriented Recovery Enhancement (MORE) on their NIDA Notes page. NIDA Notes has provided in-depth coverage of research findings on drug abuse and addiction for the past 25 years. Each month, 2-4 research articles from the entirety of addiction science are covered on NIDA’s webpage, so this is great recognition for the MORE research program.

We previously demonstrated that MORE can reduce chronic pain patients’ misuse of opioids (Garland et al., 2014, Journal of Consulting and Clinical Psychology). Now, a follow-up analysis of data from that study found these reductions in opioid misuse to be associated with an increase in patients’ cardiac-autonomic responsiveness to cues for natural rewards relative to cues for drug rewards (Garland et al., 2017, Psychotherapy and Psychosomatics). This is one of the most important discoveries I have made in the past decade, and suggests that MORE may reduce risk for opioid misuse by increasing physiological sensitivity to natural rewards. Thus, using mindfulness to amplify savoring of natural, healthy pleasures and promote meaning in life may be an antidote to opioid misuse, a condition that has been called a “disease of despair.”

Mindfulness-Based Treatment of Addiction: Current State of the Field and Envisioning the Next Wave of Research

I am pleased to announce that my colleague Matthew Howard and I had a new, invited manuscript accepted in the journal Addiction Science and Clinical Practice, an open access forum for clinically-relevant research that was previously published by the National Institute on Drug Abuse. The abstract for this paper (which is freely available to the public), entitled Mindfulness-Based Treatment of Addiction: Current State of the Field and Envisioning the Next Wave of Research is appended below:

“Contemporary advances in addiction neuroscience have paralleled increasing interest in the ancient mental training practice of mindfulness meditation as a potential therapy for addiction. In the past decade, mindfulness-based interventions (MBIs) have been studied as a treatment for an array addictive behaviors, including drinking, smoking, opioid misuse, and use of illicit substances like cocaine and heroin. This article reviews current research evaluating MBIs as a treatment for addiction, with a focus on findings pertaining to clinical outcomes and biobehavioral mechanisms. Studies indicate that MBIs reduce substance misuse and craving by modulating cognitive, affective, and psychophysiological processes integral to self-regulation and reward processing. This integrative review provides the basis for manifold recommendations regarding the next wave of research needed to firmly establish the efficacy of MBIs and elucidate the mechanistic pathways by which these therapies ameliorate addiction. Issues pertaining to MBI treatment optimization and sequencing, dissemination and implementation, dose–response relationships, and research rigor and reproducibility are discussed.”

Research on Mindfulness-Oriented Recovery Enhancement Discussed at NIH to Address the Opioid Crisis

NIH 5

I participated in the invitation-only NIH meeting “Contributions of Social and Behavioral Research in Addressing the Opioid Crisis” on March 5-6, 2018 (for a link to the webcast of the entire meeting, click here).  This meeting was part of the series of NIH meetings on Cutting Edge Science to End the Opioid Crisis.  The goals of this meeting were to: 1) specify the key social and behavioral science findings that can be brought to bear immediately to address the opioid crisis and 2) identify critical short-term research priorities that have to the potential to improve the opioid crisis response. The meeting participants represented some of the most accomplished researchers involved in the social and behavioral research relevant to the opioid crisis as well as senior leaders of various federal agencies and national organizations. I was tremendously honored to be invited as a subject matter expert to present my research to inform real-world policy and practice initiatives to address the opioid crisis.

I spoke on a panel entitled “Incorporating Nonpharmacologic Approaches to the Treatment of Opioid Abuse and Chronic Pain Management” along with luminaries in the pain research field including Francis Keefe (Duke University), Dennis Turk (University of Washington), and Dan Cherkin (Kaiser Permanente). In my talk, I discussed my research on Mindfulness-Oriented Recovery Enhancement (MORE) as a treatment for chronic pain and opioid misuse, and emphasized hedonic dysregulation (e.g., anhedonia) as a pathogenic process in opioid misuse/addiction and a key mechanistic target for novel behavioral therapies.

We presented our work to federal administrators including Francis Collins (Director of the National Institutes of Health), Nora Volkow (Director of the National Institute on Drug Abuse), Eliseo Pérez Stable (Director of the National Institute on Minority Health and Health Disparities), William Riley (Director of the Office of Behavioral and Social Science Research), David Shurtleff (Acting Director of the National Center for Complementary and Integrative Health), David Atkins (Director of Health Services Research and Development Service, U.S. Department of Veteran Affairs), and Sherry Ling (Deputy Chief Medical Officer of the Center for Clinical Standards and Quality, Centers for Medicare and Medicaid Services).

Areas of focus at the meeting included discussion of 1) Sociocultural and Socioeconomic Underpinnings of the Opioid Crisis in the United States; 2) Behavioral and Social Factors Preventing Opioid Initiation and Mitigating the Transition from Acute to Chronic Opioid Use; 3) Incorporating Nonpharmacologic Approaches to the Treatment of Opioid Abuse and Chronic Pain Management; 4) Prevention, Treatment and Recovery: Challenges and Barriers to Implementation; and 5) Effective Models of Integrated Approaches.

To summarize the meeting, research leaders and healthcare policy makers were highly focused on implementation and dissemination of evidence-based interventions and practices to target opioid misuse in chronic pain patients and to prevent/treat opioid addiction among those who have transitioned to illicit opioid use. There was much emphasis on the role of negative affect (e.g., despair), suicidality, and trauma as precipitants and correlates of opioid addiction, and the role of social support and meaningful engagement as protective factors against opioid addiction. Non-pharmacologic approaches (specifically, mindfulness and cognitive-behavioral therapy) were directly highlighted as empirically supported means of treating chronic pain and preventing opioid addiction. Finally, there was much discussion of the need to advance integrative treatment models that combine medication assisted treatment (e.g., buprenorphine, methadone) with behavioral interventions (e.g., mindfulness, exercise/physical therapy) to stop the crisis.

I was particularly struck by the framing of the opioid crisis as a “disease of despair” driven by socioeconomic disparity and disenfranchisement. Early in the morning on March 5, Nobel Prize winning economist Angus Deaton presented his work showing that mortality by opioids, alcohol, and suicide is differentially elevated in U.S. counties struck by structural inequalities. If opioid misuse and addiction are diseases of despair, then therapies like Mindfulness-Oriented Recovery Enhancement that aim to enhance joy and meaning in life may be a key part of the much-needed multifaceted solution to the greatest public health crisis of our era.

 

Mindfulness-Oriented Recovery Enhancement Covered on NPR

National Public Radio recently covered a story on Mindfulness-Oriented Recovery Enhancement (MORE) as an intervention for chronic pain and prescription opioid-related problems. The story details new discoveries about the biobehavioral mechanisms of this novel therapy, as well as how mindfulness can be used to improve well-being in individuals suffering from chronic pain.

The NPR story can be found here.

 

 

Center on Mindfulness and Integrative Health Intervention Development (C-MIIND)

The University of Utah has launched a new center dedicated to providing a transformative influence on healthcare by unifying research on mindfulness and other integrative behavioral health interventions.

Eric Garland, Associate Dean for Research at the U’s College of Social Work, will serve as Director of the new Center on Mindfulness and Integrative Health Intervention Development (C-MIIND). The Center, which will assume oversight of more than $17 million in federal research grants, will be housed in the College of Social Work.

“The center will advance a vision of a new model of healthcare, in which behavioral health experts work in tandem with medical providers to address the physical, psychological and social needs of people suffering from an array of health conditions,” said Garland, whose research focuses on using mindfulness to help individuals who experience chronic pain.

The center will bring together researchers and clinicians from across main campus and University of Utah Health, including faculty in social work, psychiatry, primary care, anesthesiology, neuroscience, oncology, psychology, and health, who are pioneering integrative interventions aimed at improving physical and mental well-being. C-MIIND will strive to attract top faculty and provide research opportunities for undergraduate, graduate and post-doctoral fellows interested in studying mindfulness and integrative behavioral health.

A focus of the center also will be to train post-graduates and health care providers in innovative therapies to be used in primary care clinics, hospitals, community mental health centers and addiction treatment facilities.

News coverage of the Center launch can be found here.

An NPR interview with Dr. Garland about the Center can be found here.

 

First fMRI Pilot Study Published on the Effects of Mindfulness-Oriented Recovery Enhancement on Reward Processing in Addiction

IMORE-fMRI-SB‘m pleased to announce that the first fMRI brain imaging study of Mindfulness-Oriented Recovery Enhancement (MORE) has been published in the open-access journal Evidence-Based Complementary and Alternative Medicine (Froeliger et al., 2017). My colleague Brett Froeliger and I conducted this proof-of-concept pilot study at his TRAIN Lab at the Medical University of South Carolina to examine the effects of MORE on reward processes in the brains of people addicted to cigarettes. A sample of 13 smokers participated in a study testing MORE versus a comparison group. All participants underwent two fMRI scans 8 weeks apart. Between the first and second fMRI scan, participants in the MORE group learned mindfulness and reappraisal skills to decrease addictive reactions to cigarettes and savoring skills to increase responsiveness to natural rewards (e.g., social connection, natural beauty, healthy behaviors). Participants in the comparison group completed research measures but did not receive any treatment. Relative to the comparison group, MORE was associated with significant decreases in smoking (66% decrease) and significant increases in positive emotions. Crucially, MORE participants evidenced significant decreases in neural activity while viewing cigarette images in reward-related brain regions including the ventral striatum and ventromedial prefrontal cortex. MORE participants also demonstrated significant increases in neural activity in these same reward-related brain regions while they savored positive, natural-reward related images. Importantly, increases in brain activity during savoring were significantly correlated with smoking reduction and increased positive affect. These pilot findings provide preliminary evidence that MORE may facilitate the restructuring of reward processes and play a role in treating the pathophysiology of nicotine addiction. These findings converge with results from our other psychophysiological studies indicating that MORE may restructure reward processes in prescription opioid misuse (Garland, Froeliger, & Howard, 2014; Garland, Froeliger, & Howard, 2015; Garland, Howard, Zubieta, & Froeliger, 2017). Taken together, these data provide initial support for my restructuring reward hypothesis which asserts that mindfulness training may enhance a domain-general cognitive resource for restructuring reward learning from valuation of drug-related rewards to valuation of natural rewards and thereby reverse the downward spiral of addiction.

New R01 Grant from the National Institute on Drug Abuse: Targeting Chronic Pain and Prescription Opioid Misuse in Primary Care with Mindfulness-Oriented Recovery Enhancement

nidaRecently, I was awarded a R01 grant from the National Institute on Drug Abuse to conduct a full-scale clinical trial of Mindfulness-Oriented Recovery Enhancement (MORE) as an intervention to reduce chronic pain and prescription opioid misuse in primary care. This five-year study will compare the efficacy of MORE to supportive therapy for 260 chronic pain patients receiving long-term opioid therapy who are at risk for opioid misuse.

Opioids may be medically necessary for some individuals experiencing prolonged and intractable pain, and most patients take medicine as prescribed. Unfortunately, opioids rarely completely alleviate chronic pain, and when taken in high doses or for long periods of time, can lead to serious side effects, including death by overdose, as well as risk for opioid misuse, which affects about 1 in 4 opioid-treated patients. Misusing opioids by taking higher doses than prescribed or by taking opioids to self-medicate negative emotions can alter the brain’s capacity for hedonic regulation, making it difficult to cope with pain (e.g., causing hyperalgesia – an increased sensitivity of the nervous system to pain) and experience pleasure in life (e.g., reducing sensitivity of the brain to natural reward). As such, non-opioid pain treatments that target hedonic dysregulation may be especially helpful for reducing chronic pain and prevent opioid misuse.

Multiple studies suggest that MORE improves hedonic regulation in the brain, resulting in decreased pain and an increased ability to savor natural, healthy pleasure. People who participate in MORE show heightened brain and body responses to healthy pleasures, and report feeling more positive emotions by using of mindfulness as a tool to enhance savoring. These therapeutic effects of MORE on savoring may be critically important, because findings from several studies show that increasing sensitivity to natural reward through savoring may lead to decreased craving for drugs – a completely novel finding for the field of addiction science (Garland, 2016). Our NIDA-funded R01 will provide a rigorous test of whether MORE improves chronic pain and opioid misuse by targeting hedonic dysregulation.

In our NIDA-funded R01, patients are receiving MORE at community medical clinics throughout Salt Lake City. Providing MORE in the naturalistic setting where most chronic pain patients seek medical care will make the therapy accessible to the people who need it the most. Ultimately, my hope is that this project will advance a new form of integrative healthcare, in which doctors and nurses work alongside social workers and other behavioral health professionals to help patients reclaim a meaningful life from pain.

New Interview by Mind and Life Institute

mind_and-_lifeI was recently interviewed by Michael Juberg for the Mind and Life Institute, the world’s premier multi-disciplinary organization for the study of contemplative science. Michael and I had a wide ranging discussion that covered the span from philosophy to science to alleviating human suffering. He asked me some seriously thought-provoking questions that made me reflect back on the roots of my career and where it is all headed in the future. At the end of the interview, I offered a bit of advice for folks aspiring to become scientists in this field. The interview was really well done and I’m pleased to share it with you here.

New Research Funding: Neuroimaging Research on the Effects of Mindfulness-Oriented Recovery Enhancement on Hedonic Regulation

mindfulness-centered-regulation-in-brainChronic pain is often treated with extended use of opioid analgesics, yet these drugs can alter the brain in ways that may make it difficult to cope with pain and may reduce the experience pleasure in life. Mindfulness-based interventions appear to be a promising means of addressing these issues, but research is needed to understand how such interventions change the brain to reduce suffering.

To that end, in September, 2016, I was recently awarded a five-year phased innovation grant from the National Institutes of Health’s (NIH) National Center for Complementary and Integrative Health entitled Effects of Mindfulness-Oriented Intervention on Endogenous Opioid Mechanisms of Hedonic Regulation in Chronic Pain (R61AT009296). The objective of the project is to study the effects of an innovative mindfulness-based intervention on brain mechanisms linked with pain and pleasure.

In the first two-year phase of the study ($800,000), I (Principal Investigator), along with my Co-Principal Investigator Jon-Kar Zubieta (Co-Principal Investigator), chair of the University of Utah’s Department of Psychiatry, will use positron emission tomography (PET) neuroimaging to assess the effects of Mindfulness-Oriented Recovery Enhancement (MORE) on restoring brain levels of endorphins in patients with chronic back pain who are being treated with prescription opioids.

This study represents the first use of PET in the history of science to quantify the effects of a mindfulness-based therapy on levels of endogenous opioids in the brain.

We will also use functional magnetic resonance imaging (fMRI) methods to assess how mindfulness training through MORE may increase people’s capacity to savor natural pleasure from positive and meaningful events in everyday life – a capacity that becomes diminished over time through the deleterious effects of chronic pain and prolonged opioid use on the brain. We will use a fMRI paradigm developed by my Co-Investigator Brett Froeliger, Assistant Professor of Neuroscience at the Medical University of South Carolina.

This study aims to test whether MORE might reverse this insensitivity to natural reward by targeting the endogenous opioid system and brain reward functions.

Following a successful first phase of the project, a three-year second phase ($2.2 million) will investigate whether patients with a particular genetic makeup that affects the expression of opioid receptors in the brain might benefit more from the mindfulness-based treatment. The second phase of the project will also assess the dose of mindfulness skill practice as a predictor of changes in endogenous opioid function and clinical correlates.

Based on the results of previous research, we hypothesize that mindfulness meditation training through MORE will restore proper function to the brain’s opioid receptors.  We will be able to measure how MORE changes the brain’s ability to regulate pain and respond to natural rewards, as well as deepen our understanding of exactly how these changes in neural mechanisms happen.

more-conceptual-framework-opioid

Overall, this project will unite expertise in mindfulness-based interventions with expertise in neurogenetics and the use of PET and fMRI to probe the neurobiological mechanisms of pain and emotional experience. By elucidating a key mechanism of meditation-based therapies, this program of translational research will further the emerging field of social work neuroscience and enable us to rapidly optimize MORE to increase the effectiveness of the intervention as it is rolled out in clinical practice.

 

 

New Research Funding: Targeting Chronic Pain among Veterans and Military Personnel with Mindfulness-Oriented Recovery Enhancement

 

mind-reappraise-savor-brain

I was recently awarded $3.4 million in research funding from the Department of Defense Congressionally Directed Medical Research Program for a five-year clinical trial award entitled “Targeting Chronic Pain and Co-Occurring Disorders in the Community with Mindfulness-Oriented Recovery Enhancement.” To help me to carry out this pragmatic, large-scale randomized controlled trial, I will be supported by an interdisciplinary team of expert co-investigators from the University of Utah, including Jon-Kar Zubieta, Craig Bryan, Yoshio Nakamura, Gary Donaldson, and Bill Marchand.

The co-occurrence of chronic pain, psychological distress, and misuse of prescription opioids undermines the mission of the U.S. Military and inflicts suffering upon Veterans and their families. Approximately one-half of service members have chronic pain following deployment, and nearly one-fifth engage in opioid misusing behaviors like unauthorized dose escalation and use of opioids to self-medicate stress and anxiety. The state of Utah (where the proposed study will be conducted) has one of the highest incidences of nonmedical use of opioids in the U.S. and a rapidly increasing rate of prescription opioid-related deaths. Indeed, an estimated 21% of Utah adults were prescribed opioids during the past year, of which approximately one-in-five report taking more than prescribed. Given that military personnel and Veterans have higher rates of pain-related conditions than the general population, their risk for opioid-related problems is significantly enhanced.

military

New scientific findings indicate that because stress worsens pain and increases habit responses in the brain, individuals who cope with stress and pain through opioids are likely to have the most serious and difficult-to-treat opioid-related problems. The recent wars in Iraq and Afghanistan have been marked by repeated deployments involving serious combat-related and occupational stress. Unfortunately, there are no evidence-based treatments that simultaneously address pain, opioid misuse, and psychological distress. To fill this gap, this research proposal aims to conduct a pragmatic trial of a novel integrative medicine approach combining Mindfulness-Oriented Recovery Enhancement (MORE) with conventional opioid pain management for service members and Veterans. MORE aims to strengthen self-control over habit behaviors, increase flexible thinking under conditions of stress, and promote the sense of reward and meaning in the face of adversity.

This research project will help active duty service members and Veterans with chronic pain and stress who are at-risk for opioid misuse, and will also inform the treatment of civilians with similar issues. Should MORE prove to be effective in a community-based context, it could be easily transported into military installations and Veterans Administration Medical Centers in the U.S. and around the world, as well as in communities where no major military medical center is present. In these settings, MORE could be offered as a form of standard integrative health care provided to service members and Veterans.

A secondary objective of the proposed project is to utilize lab-based assessments and mobile technology to understand how MORE works to create therapeutic change, and to predict whether and when service members and Veterans are at risk for relapsing back to opioid misuse. To accomplish this objective, lab-based assessments will evaluate physiological reactivity to cues associated with past episodes of pain and opioid use, and a smartphone-based assessment will be used to evaluate opioid craving, pain, and negative mood in “the real world.” Because changes in heart rate and other physiological factors may indicate the extent to which a person’s brain has been triggered by opioid craving, this application of mind-body assessments to predict opioid misuse risk and treatment outcomes could facilitate early risk detection.

The final objective of the project is to understand for whom MORE works best, to help ensure more efficient healthcare resource allocation to the service members and Veterans who need it most.  The proposed project will enable health care providers to more effectively deliver low-cost treatment to prevent progression toward opioid addiction, thereby averting costly inpatient stays, discharge from active duty military service, and social, legal, and occupational problems among Veterans. Ultimately, the proposed research could significantly enhance the psychological and physical health of military personnel and Veterans by addressing the need for new integrative medicine treatment options with findings from the leading edge of science.

Research on MORE in the Annals of the New York Academy of Sciences – Targeting Hedonic Dysregulation with Mindfulness-Oriented Recovery Enhancement

mindfulness centered regulationIt is my pleasure to announce that the very first review paper summarizing the theoretical rationale and empirical evidence for Mindfulness-Oriented Recovery Enhancement (MORE) has been accepted for publication in the prestigious journal Annals of the New York Academy of Sciences. In this paper, I review data from multiple clinical studies on the biobehavioral mechanisms of MORE, and articulate a hedonic regulatory model of the intervention – proposing that restructuring reward processing is the final common pathway through which MORE ameliorates addiction, stress, and pain. I map this novel theoretical model onto an earlier conceptual framework of the neural circuitry underlying mindfulness-centered regulation of addiction (Garland, Froeliger, & Howard, 2014) and then describe new neuroimaging and psychophysiological data in support of the model. The paper abstract is as follows:

“Though valuation processes are fundamental to survival of the human species, hedonic dysregulation is at the root of an array of clinical disorders including addiction, stress, and chronic pain, as evidenced by the allostatic shift in the relative salience of natural reward to drug reward observed among persons with severe substance use disorders. To address this crucial clinical issue, novel interventions are needed to restore hedonic regulatory processes gone awry in persons exhibiting addictive behaviors. This article describes theoretical rationale and empirical evidence for the effects of one such new intervention, Mindfulness-Oriented Recovery Enhancement (MORE), on top-down and bottom-up mechanisms implicated in cognitive control and hedonic regulation. MORE is innovative and distinct from extant mindfulness-based interventions in that in unites traditional mindfulness meditation with reappraisal and savoring strategies designed to reverse the downward shift in salience of natural reward relative to drug reward, representing a crucial tipping point to disrupt the progression of addiction – something that no other behavioral intervention has been designed to do. Though additional studies are needed, clinical and biobehavioral data from several completed and ongoing trials suggest that MORE may exert salutary effects on addictive behaviors and the neurobiological processes that underpin them.”

News: Dr. Garland’s Biobehavioral Research on MORE and Mindful Savoring Highlighted by the National Institute on Drug Abuse

MORE Reward ERPI recently learned that my research on Mindfulness-Oriented Recovery Enhancement (MORE) was highlighted on the National Institute on Drug Abuse website. The NIDA news story, entitled “Mindfulness training may reduce deficits in natural reward processing during chronic pain or drug addiction” details a study I conducted with my colleagues Brett Froeliger (Neuroscience, Medical University of South Carolina) and Matthew Howard (Social Work, University of North Carolina at Chapel Hill) that was published in April in the Journal of Behavioral Medicine. According to the excellent summary of this research on the NIDA website,

“Drug-dependent people show decreased behavioral and brain reactivity to natural rewards compared to non-drug users. As a result, drug-dependent users increasingly focus their attention on obtaining the drug instead of attending to natural rewards.  Recent research shows that a cognitive-based intervention may help restore natural reward processing in opioid-dependent participants.

In this study, chronic pain patients at risk for opioid misuse were randomized to either eight weeks of a Mindfulness-Oriented tetonsRecovery Enhancement (MORE) intervention or to an eight-week support group (control). Participants in the MORE intervention used mindfulness meditation to focus on all sensory features of a pleasant experience or object (for example, a beautiful nature scene like a sunset), while reflecting on any positive emotions arising in response to the pleasant event. The support group discussed topics and emotions related to chronic pain and opioid use/misuse. Following these interventions, all participants were shown images representing natural rewards (such as endearing animals, appealing foods, landscapes) or neutral images (furniture, neutral facial expressions, or household items). Researchers measured late positive potential (LPP) brain activity, which reflects attention to emotionally salient information, while participants viewed these images. In comparison to the control group, participants completing the MORE intervention showed greater LPP responses to natural reward images relative to neutral images and greater the LPP responses predicted reduced opioid cravings as reported by the participants.”

These results suggest that teaching people who misuse opioids to mindfully attend to positive aspects of their life may increase the perceived value of natural rewards – processes that may be diminished in those facing chronic pain or addiction – which may in turn help them to control opioid cravings.”

It is thrilling to see that this line of research is making a positive impact on the scientific community, and of course, the ultimate aim of this work is to alleviate human suffering.

News: Dr. Garland’s Article Ranked in 93rd Percentile! – Mindfulness Training Targets Neurocognitive Mechanisms of Addiction at the Attention-Appraisal-Emotion Interface

An article I published with my colleagues Brett Froeliger from MUSC and Matthew Howard from UNC Chapel Hill in the journal Frontiers in Psychiatry entitled “Mindfulness training targets neurocognitive mechanisms of addiction at the attention-appraisal-emotion interface” was designated in the 93rd percentile of 3,480,147 articles tracked by Altmetric. The Altmetric score is a measure of the quality and quantity of online attention that this article has received. The paper details the model depicted below.

mindfulness centered regulation

In this review paper, we describe how mindfulness-based interventions (MBIs) may target neurocognitive mechanisms of addiction at the attention-appraisal-emotion interface. Empirical evidence is presented suggesting that MBIs ameliorate addiction by enhancing cognitive regulation of a number of key processes, including: clarifying cognitive appraisal and modulating negative emotions to reduce perseverative cognition and emotional arousal; enhancing metacognitive awareness to regulate drug-use action schema and decrease addiction attentional bias; promoting extinction learning to uncouple drug-use triggers from conditioned appetitive responses; reducing cue-reactivity and increasing cognitive control over craving; attenuating physiological stress reactivity through parasympathetic activation; and increasing savoring to restore natural reward processing. Treatment and research implications of our neurocognitive framework are presented. We conclude by offering a temporally sequenced description of neurocognitive processes targeted by MBIs through a hypothetical case study. Our neurocognitive framework has implications for the optimization of addiction treatment with MBIs.

The paper is free for download here.